$37 million will invest by foreign investor in a pharmaceutical plant in South Kazakhstan, reports press service of Kazakhstan’s Ministry of Investment and Development.

The money will spend on the further modernization of the largest pharmaceutical plant in Kazakhstan.

‘Development of the IT infrastructure, production digitization, improvement and automation of quality control and quality assurance system, development. Development of new medicines are the main objectives of the fourth stage of the investment program of the international group Polpharma for 2018-2022 with an investment volume of $ 37 million’, the department informed.

In March, they plan to launch a new section of non-sterile solutions. Until 2022, the factory will build a new laboratory, update the infrastructure, and modernize the logistics facilities. In addition, the plant is waiting for new equipment for research and development.

‘In fact, today the plant has completed the construction and modernization of all major production facilities and auxiliary logistic sites. The investment program will focus on new projects in the field of digitalization and automation of production and support processes, and projects in the field of quality management and quality control’, said the director of the plant of JSC "Himfarm" Rustam Baigarin.

The reason for the investment is long-term contracts for the supply of medicines for medical institutions in Kazakhstan, mentioned company. Also, the company has already registered 115 drugs covering 12 pharmacological groups.

“The Qazaq Times”